In particular, combination of CAR T-cell therapies with immune checkpoint inhibitors, mainly anti-PD1 and anti-PDL1, may significantly increase the anti-tumor immunity in lymphomas, paralleling the suggestions and observations in solid tumors [108]. The gene discussed is CD274; the disease is neoplasm.